JPRN-UMIN000006977已完成2 期
Randomized Phase II trial of palonosetron, aprepitant plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by chemotherapy for breast cancer - Randomized Phase II trial of palonosetron, aprepitant plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by chemotherapy for breast cancer(KBCSG02)
Kitasato University School of Medicine Department of Surgery0 个研究点目标入组 80 人开始时间: 2011年12月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients who has a convulsive disorders that need anticonvulsants therapy. 2)With nausea (CTCAE Grade2). 3)A history of sever allergic reaction with palonosetron or aprepitant or dexamethasone. 4)Pregnancy or the desire to preserve fecundity. 5)Receiving an antiemetic drug. 6)Receiving pimozide. 7)With mental disease or psychotic manifestation. 8)Any patients judged by the investigator to be unfit to participate in the study.
研究者
相似试验
已完成
2 期
Phase II trial of palonosetron, aprepitant plus dexamethasone in the prevention of nausea and vomiting induced by chemotherapy for urothelial cancer.rothelial cancerJPRN-UMIN000008629rology, Department of Medicine Kitasato University, School of Medicine45
已完成
2 期
Phase II trial of palonosetron, aprepitant plus dexamethasone in the prevention of nausea and vomiting induced by hepatic arterial injection chemotherapy with cisplatin for Hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000007265Gastroenterology, Department of Medicine Kitasato University, School of Medicine45
尚未招募
2 期
Randomized Phase II trial of Palonosetron/Dexamethasone concurrent therapy with prevention of CINV according to chemotherapy including Oxaliplatin or Irinotecan in patients with advanced colorectal cancer.JPRN-UMIN000005534ara Hospital Kinki University Faculty of Medicine80
已完成
3 期
A randomized phase III trial of palonosetron versus palonosetron plus dexamethasone (day1) for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy (HOPE-02)Colorectal CancerJPRN-UMIN000013249HOPE group(Hokkaido Supportive Care Oncology Project - an Expert Group Initiative)320
进行中（未招募）
不适用
Phase II study with Palonosetron alone in preventing chemotherapy-induced nausea and vomiting in untreated patients with aggressive Non Hodgkin?s Lymphomas who underwent moderately emetogenic chemotherapy - Palonosetron in NHpreventing chemotherapy-induced nausea and vomiting in untreated patients with aggressive Non Hodgkin?s Lymphomas who underwent moderately emetogenic chemotherapy.MedDRA version: 9.1Level: HLTClassification code 10028817Term: Nausea and vomiting symptomsEUCTR2006-003189-33-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI